+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 100Years
All Genders
ID03206060

Investigating Lu-177-DOTATATE Lutathera for Treatment of Inoperable Pheochromocytoma and Paraganglioma Tumors

Led by National Cancer Institute (NCI) · Updated on 2026-10-26

130

Participants Needed

1

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Pheochromocytoma and paraganglioma are rare tumors that develop in or near the adrenal gland or neck region. These tumors can be difficult to remove with surgery, especially if they have spread, and current treatments for advanced cases are limited. Researchers are evaluating the safety and tolerability of Lu-177-DOTATATE and its potential to extend the time before the cancer returns in people with inoperable, somatostatin receptor-positive tumors. Participants will receive Lu-177-DOTATATE through an intravenous infusion every 8 weeks for a total of four doses. Alongside the drug, an amino acid solution will be infused to protect the kidneys. After each treatment, participants will have scans including Ga-68-DOTATATE PET, F-18-FDG PET, CT, and MRI to monitor the tumors. Imaging and blood tests will be performed throughout the study to track treatment effects and safety. During the study, participants will undergo regular assessments including physical exams, blood and urine tests, and quality of life questionnaires. Follow-up will occur every 3 to 6 months for up to 3 years or until the disease worsens, with additional yearly contacts thereafter. Researchers will measure progression-free survival at 6 months as the primary outcome along with tumor progression time, overall survival, safety, and changes in biochemical markers and medication use.

CONDITIONS

Brief Title

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Research Team

J

Joy H Zou, R.N.

F

Frank I Lin, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here